SOPHiA GENETICS, a cloud-native software company in the healthcare space, announced a new partnership with QIAGEN N.V that will pair QIAseq reagent technology with the SOPHiA DDM platform to enhance tumor analysis through next-generation sequencing (NGS).
WebsiteHost.Review Interview : WebsiteHost.Review Interview with Lori Anne, Director of Product Development & Management at Verizon
“SOPHiA’s mission is to democratize data-driven medicine. To get there, we are partnering with reagent manufacturers so that our deep expertise in genomic analysis complements their solutions”
The partnership will allow customers to order QIAseq panels that can be processed through SOPHiA DDM
“SOPHiA’s mission is to democratize data-driven medicine. To get there, we are partnering with reagent manufacturers so that our deep expertise in genomic analysis complements their solutions,” said Kevin Puylaert, VP Business Development at SOPHiA GENETICS. “We have a strong and longstanding relationship with QIAGEN and have used their products as part of our ‘bundle solution’ for years. QIAGEN’s amplicon-targeted NGS technology has an outstanding reputation to be among the best. We are taking full advantage of the performance of both solutions in this collaboration and are very optimistic about the positive impact on medicine and research.”
“Our Platform Partnership Program will enable more customers to benefit from the high quality of the QIAGEN NGS preparation kits through the use of a wider range of analytics solutions to address their unique analysis and interpretation needs,” said Thomas Schweins, Senior Vice President of the Life Sciences Business Area at QIAGEN. “SOPHiA GENETICS is our first partner thanks to their deep and unique expertise and reputation. We look forward to offering our customers a combination of best-in-class solutions and expanding our collaboration.”
Read More Interview: WebsiteHost.Review Interview with Mario Ciabarra, Founder and CEO of Quantum Metric
The applications of SOPHiA DDM
The partnership with SOPHiA GENETICS is planned to be expanded to other areas of analysis, including the use of QIAseq panels custom-made solutions. It is the inaugural partnership in QIAGEN’s QIAseq Platform Partnership.
NGS has the potential to revolutionize the diagnosis and treatment of cancers and rare diseases but creates extremely large, complex, and noisy datasets for analysis. Without the right analytical technology, pinpointing causative variants and obtaining actionable insights from NGS data requires specialist skills, multiple resources, and considerable time. The SOPHiA DDM
Latest Interview Insights : WebsiteHost.Review Interview with Jessica Stafford, SVP of Consumer Solutions at Cox Automotive
[To share your insights with us, please write to admin@websitehost.review]
The post Sophia Genetics And Qiagen Forge Partnership To Combine Strengths In Next-generation Sequencing appeared first on WebsiteHost.Review.
Opposition to data center developments has been spreading due to local issues such as rising…
TL;DR While cloud computing has traditionally been defined by speed, scale, and flexibility, mature environments…
TL;DR AI and cloud demand are expanding Latin America’s digital infrastructure opportunity while increasing requirements…
TL;DR Lightpath has entered the Greater Atlanta market with high-capacity Managed Bandwidth services. Wavelength and…
TL;DR Earnings release: Duos will report second quarter 2026 results after market close on Friday,…
TL;DR Defining the Distinction: “Modular” construction encompasses two main approaches—traditional prefabrication (assembling components like electrical…